News ArticleMore News »
Pina D' Angelo was invited to be a panelist at The 2017 ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop
Sep 18, 2017
The ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop was originally a meeting for U.S. Food and Drug Administration (FDA) statisticians that later expanded to include all statisticians interested in statistical practices for all areas regulated by the FDA. Today, The ASA intends to bring both the FDA and industry speakers into each session. As a result, it has magnified the value of the conference and it has become the most relevant conference for statistical practitioners in the biopharmaceutical arena.
However, the ASA limits the number of attendees and presenters to an exclusive group of biopharmaceutical experts. Pina D’Angelo, MSc, Novum’s Executive Director, Scientific Affairs (Biostatistics), was a panelist for the session titled “Statistical Evaluation of Generic Transdermal Delivery Systems and to Tropical Patches” on September 26, 1:15PM - 2:30PM.This session provided an overview of the challenges when analyzing studies with transdermals and topical patches.
For over 40 years, Novum has been considered one of the world’s leaders in the conduct of clinical trials; Early Phase Research from First in Human studies to large bioequivalence studies are conducted at Clinical Pharmacology units in Houston, Texas; Las Vegas, Nevada; and Fargo, North Dakota. A separate division, managing Late Phase Research requiring patient populations across multiple therapeutic areas, is lead by the Clinical Trials Division headquartered in Pittsburgh, Pennsylvania.